FLC On Enhancing Geographic Footprint And Financing Capacity

For financing of Build, Own, Operate & Transfer projects the company has secured a US $50.0 million non-recourse debt facility and is making an announcement around this. With widespread experience in renewable energy projects and financing infrastructure the facility is provided by a leading US-based sustainable infrastructure investment firm.

Across projects in different geographies this single facility may be deployed, most importantly thus significantly restructuring one of the most intense steps in project development. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]

‘Towards the future it is a big step particularly for the fleet of smart packaged systems to undertake projects that use their proven expertise in project execution which will now have readily available access to the funding needed. Fluence CFO Francesco Fragasso said while commenting on the new debt facility.

To deliver in China multiple MABR-based Aspiral smart packaged solutions, the company was also recently seen announcing a new partnership and another contract award. This achievement of contract for a 1,500 m3 /day wastewater treatment plant and new partnership with environmental EPC firm Zhongi Hause, in Jilin Province, are the first for Fluence. The contract requires to be commissioned and operating by January 2019 and contract requires to be delivered by December 2018 another six Aspiral L5 units.

Fluence’s MABR-based Smart Packaged Aspiral because of its reduced need for active aeration can be adapted to perform efficiently under challenging conditions. Further opportunities in extremely cold regions may be because of the successful execution of this project. The company is expanding its footprints in China by signing this multi-unit Aspiral order for the use of rural wastewater treatment.

Fluence Corporation Ltd (ASX: FLC) has surged up by 2.703% on the ASX as at November 30, 2018 to trade at a market price of $0.380. This is near its 52-week low and the company has seen a performance change of -3.90% over the past one month.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

 

 

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report